title: The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia.
abstract: OBJECTIVE
  This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML).
  
  
  METHODS
  After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days.
  
  
  RESULTS
  The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%).
  
  
  CONCLUSIONS
  The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Min
authors.forename: Cheol Won
authors.initials: CW
authors.lastname: Suh
authors.forename: Keon Uk
authors.initials: KU
authors.lastname: Park
authors.forename: Sung Soo
authors.initials: SS
authors.lastname: Yoon
authors.forename: Chan Hyung
authors.initials: CH
authors.lastname: Park
authors.forename: Hong Ghi
authors.initials: HG
authors.lastname: Lee
keywords: Acute myelogenous leukemia; Neutropenia; rhG-CSF